New Science Ventures leads Novadip’s €10.4 million convertible financing round

By Public Technologies
  • New Science Ventures led Novadip’s € 10.4 million convertible financing round disclosed Sept. 21, 2026.
  • Novadip is a late-stage regenerative medicine biotech developing cell-based therapies for bone repair.
  • Proceeds fund completion of a pivotal Phase 3 trial for NVD003 in congenital pseudarthrosis of the tibia.
  • Round lifts Novadip’s total convertible financing to € 20 million, including a prior € 9.6 million convertible loan.
  • Financing unlocks the final tranche of an € 18 million EIB venture debt facility signed in 2023.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. New Science Ventures LLC published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.